Purpose There is currently no standard treatment strategy for patients with advanced metastatic
gastric cancer experiencing progression after two or more lines of chemotherapy. We …

Purpose: We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1)
mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced …

Background Patients with advanced or metastatic oesophageal squamous cell carcinoma
have poor prognosis and few treatment options after first-line therapy. We aimed to assess …

Purpose Patients with metastatic gastric cancer (mGC) who do not respond to or who
experience progression with second-line chemotherapy have no treatment options that clearly …

Background Blocking the interaction between PD-1 and its ligands is a promising treatment
strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour …

Background Outcomes are poor for patients with recurrent or metastatic nasopharyngeal
carcinoma and no well established first-line chemotherapy is available for the disease. We …

Background Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic
tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-…

Background Platinum-based doublet chemotherapy regimens, preferentially gemcitabine plus
cisplatin, are generally considered the first-line standard of care for patients with recurrent …

PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind …

The tumor microenvironment (TME) in gastric cancer (GC) has been shown to be important
for tumor control but the specific characteristics for GC are not fully appreciated. We …